A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. Recent Developments In 2025, we achieved $3.2 billion in total revenues, including a significant contribution from our ongoing expansion of VOXZOGO, and we continued to grow our commercial business and advance our product candidate pipeline.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 3.2B | 3.2B | 2.9B | 2.4B | 2.1B | 1.8B |
| Net Income | 349M | 349M | 427M | 168M | 142M | -64M |
| EPS | $1.80 | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
| Free Cash Flow | 725M | 725M | 487M | 63M | 55M | 209M |
| ROIC | 5.5% | 8.4% | 10.4% | 4.7% | 4.6% | -1.5% |
| Gross Margin | 77.7% | 77.7% | 79.7% | 78.0% | 76.0% | 74.5% |
| Debt/Equity | 0.11 | 0.11 | 0.11 | 0.23 | 0.25 | 0.27 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 409M | 409M | 484M | 186M | 161M | -82M |
| Operating Margin | 12.7% | 12.7% | 17.0% | 7.7% | 7.7% | -4.5% |
| ROE | 5.7% | 5.9% | 8.0% | 3.5% | 3.2% | -1.5% |
| Shares Outstanding | 194M | 194M | 193M | 193M | 189M | 183M |
BIOMARIN PHARMACEUTICAL INC passes 3 of 9 quality checks, indicating weak fundamentals.
BIOMARIN PHARMACEUTICAL INC trades at 30.5x trailing earnings, compared to its 15-year median P/E of 30.3x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 14.6x vs a median of 26.5x. The company's 5-year average ROIC is 5.3% with a gross margin of 77.2%. At current prices, the estimated annualized return to fair value is +35.5%.
BIOMARIN PHARMACEUTICAL INC (BMRN) has a current P/E ratio of 30.5, compared to its historical median P/E of 30.3. The stock is currently considered Fair based on its historical valuation range.
BIOMARIN PHARMACEUTICAL INC (BMRN) has a 5-year average return on invested capital (ROIC) of 5.3%. This is below average and may indicate limited pricing power.
BIOMARIN PHARMACEUTICAL INC (BMRN) has a market capitalization of $10.6B. It is classified as a large-cap stock.
BIOMARIN PHARMACEUTICAL INC (BMRN) does not currently pay a regular dividend.
Based on historical P/E analysis, BIOMARIN PHARMACEUTICAL INC (BMRN) appears fair. The current P/E of 30.5 is 1% above its historical median of 30.3. The estimated fair value CAGR (P/E method) is -6.4%.
BIOMARIN PHARMACEUTICAL INC (BMRN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
BIOMARIN PHARMACEUTICAL INC (BMRN) reported annual revenue of $3.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
BIOMARIN PHARMACEUTICAL INC (BMRN) has a net profit margin of 10.8%. This is a healthy margin.
BIOMARIN PHARMACEUTICAL INC (BMRN) generated $725 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
BIOMARIN PHARMACEUTICAL INC (BMRN) has a debt-to-equity ratio of 0.11. This indicates a conservatively financed balance sheet.
BIOMARIN PHARMACEUTICAL INC (BMRN) reported earnings per share (EPS) of $1.80 in its most recent fiscal year.
BIOMARIN PHARMACEUTICAL INC (BMRN) has a return on equity (ROE) of 5.9%. This indicates moderate shareholder returns.
BIOMARIN PHARMACEUTICAL INC (BMRN) has a 5-year average gross margin of 77.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for BIOMARIN PHARMACEUTICAL INC (BMRN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BIOMARIN PHARMACEUTICAL INC (BMRN) has a book value per share of $31.40, based on its most recent annual SEC filing.